Y<sub>2</sub> receptor | Neuropeptide Y receptors | IUPHAR/BPS Guide to PHARMACOLOGY

Y2 receptor

Target id: 306

Nomenclature: Y2 receptor

Family: Neuropeptide Y receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     Currently no data for Y2 receptor in GtoImmuPdb

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 381 4q31 NPY2R neuropeptide Y receptor Y2 3,21-22,45-46
Mouse 7 385 3 E3 Npy2r neuropeptide Y receptor Y2 35,39
Rat 7 381 2q31 Npy2r neuropeptide Y receptor Y2 23
Previous and Unofficial Names
neuropeptide Y receptor type 2 | NPY-Y2 receptor
Database Links
Specialist databases
GPCRDB npy2r_human (Hs), npy2r_mouse (Mm), q9erc0_rat (Rn)
Other databases
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Natural/Endogenous Ligands
neuropeptide Y {Sp: Human, Mouse, Rat}
neuropeptide Y-(3-36) {Sp: Human, Mouse, Rat}
pancreatic polypeptide {Sp: Human} , pancreatic polypeptide {Sp: Mouse} , pancreatic polypeptide {Sp: Rat}
peptide YY {Sp: Human} , peptide YY {Sp: Mouse, Rat, Pig}
Comments: Neuropeptide Y is the principal endogenous agonist
Potency order of endogenous ligands (Human)
peptide YY = peptide YY(3-36) = neuropeptide Y = neuropeptide Y(3-36) >> pancreatic polypeptide

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]PYY Hs Full agonist 9.6 pKd 46
pKd 9.6 [46]
[125I]NPY (human, mouse, rat) Hs Full agonist 9.2 pKd 46
pKd 9.2 [46]
peptide YY {Sp: Mouse, Rat, Pig} Rn Full agonist 10.0 pKi 23
pKi 10.0 [23]
PYY-(3-36) (pig) Rn Full agonist 9.9 pKi 23
pKi 9.9 [23]
peptide YY {Sp: Human} Hs Full agonist 9.5 – 9.8 pKi 21-22
pKi 9.5 – 9.8 [21-22]
peptide YY {Sp: Mouse, Rat, Pig} Hs Full agonist 9.5 pKi 22
pKi 9.5 [22]
PYY-(3-36) {Sp: Human} Hs Full agonist 9.2 – 9.7 pKi 21-22
pKi 9.2 – 9.7 [21-22]
neuropeptide Y {Sp: Human, Mouse, Rat} Hs Full agonist 9.3 – 9.5 pKi 21-22
pKi 9.3 – 9.5 [21-22]
neuropeptide Y {Sp: Human, Mouse, Rat} Rn Full agonist 9.4 pKi 23
pKi 9.4 [23]
NPY {Sp: Pig} Hs Full agonist 9.1 – 9.3 pKi 21-22
pKi 9.1 – 9.3 [21-22]
NPY-(3-36) (pig) Hs Full agonist 9.2 pKi 21
pKi 9.2 [21]
NPY-(3-36) (pig) Rn Full agonist 9.1 pKi 23
pKi 9.1 [23]
PYY-(13-36) (mouse, rat, pig) Hs Full agonist 8.8 – 9.4 pKi 21-22
pKi 8.8 – 9.4 [21-22]
N-α-Ac-PYY-(25-36) (rat) Rn Full agonist 9.1 pKi 23
pKi 9.1 [23]
NPY-(2-36) (pig) Hs Full agonist 8.6 – 9.3 pKi 21-22
pKi 8.6 – 9.3 [21-22]
NPY-(13-36) (human) Rn Full agonist 8.9 pKi 23
pKi 8.9 [23]
N-α-Ac-PYY-(22-36) (rat) Rn Full agonist 8.8 pKi 23
pKi 8.8 [23]
NPY-(2-36) Hs Full agonist 8.8 pKi 22
pKi 8.8 [22]
NPY-(13-36) (pig) Hs Full agonist 8.6 – 8.7 pKi 21-22
pKi 8.6 – 8.7 [21-22]
C2-NPY (pig) Hs Full agonist 8.5 pKi 22
pKi 8.5 [22]
NPY-(20-36) (pig) Hs Full agonist 8.5 pKi 22
pKi 8.5 [22]
NPY-(16-36) (pig) Hs Full agonist 8.2 pKi 22
pKi 8.2 [22]
NPY-(22-36) (pig) Hs Full agonist 7.4 pKi 22
pKi 7.4 [22]
[D-Trp32]NPY Rn Full agonist 7.3 pKi 23
pKi 7.3 [23]
[D-Trp32]NPY Hs Full agonist 6.8 pKi 21
pKi 6.8 [21]
NPY-(26-36) (pig) Hs Full agonist 6.5 pKi 22
pKi 6.5 [22]
[Pro34]PYY (human) Hs Full agonist 6.3 pKi 21
pKi 6.3 [21]
[Leu31,Pro34]PYY (human) Hs Full agonist 6.2 pKi 21
pKi 6.2 [21]
[Leu31,Pro34]NPY Hs Full agonist 6.2 pKi 22
pKi 6.2 [22]
[Leu31,Pro34]NPY (pig) Hs Full agonist 6.1 pKi 21
pKi 6.1 [21]
[Ala31,Aib32]NPY (pig) Hs Full agonist 6.1 pIC50 10
pIC50 6.1 [10]
neuropeptide Y {Sp: Human, Mouse, Rat} Hs Agonist - -
peptide YY {Sp: Human} Hs Agonist - -
View species-specific agonist tables
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
BIIE0246 Rn Antagonist 8.0 pKi 23
pKi 8.0 [23]
BIIE0246 Hs Antagonist 8.5 pIC50 15
pIC50 8.5 (IC50 3.3x10-9 M) [15]
JNJ-5207787 Hs Antagonist 6.9 – 7.1 pIC50 8
pIC50 6.9 – 7.1 [8]
View species-specific antagonist tables
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
Calcium channel
References:  37,50
Secondary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  37
Tissue Distribution
Ileum and colon.
Species:  Human
Technique:  RT-PCR.
References:  17
Heart.
Species:  Human
Technique:  Immunohistochemistry.
References:  28
CNS: cortex, hippocampus, amygdala, choroid plexus, geniculate, hypothalamus, cerebellum.
Species:  Human
Technique:  in situ hybridisation.
References:  9
CNS: hypothalamus (preoptic nuclei, arcuate, dorsomedial, and perifornical nuclei, A13 dopaminergic neurons).
Species:  Mouse
Technique:  Immunohistochemistry.
References:  18
CNS: olfactory bulb, cortical areas, septum, basal forebrain, nucleus accumbens, amygdala, hippocampus, hypothalamus, substantia nigra compacta, locus coeruleus, solitary tract nucleus.
Species:  Mouse
Technique:  Immunohistochemistry.
References:  52
Large and small intestine (epithelial and nonepithelial tissue).
Species:  Rat
Technique:  RT-PCR.
References:  24
Aorta, pulmonary artery.
Species:  Rat
Technique:  RT-PCR.
References:  5
Brain: hippocampus, hypothalamus, amygdala, specific nuclei of the brainstem.
Species:  Rat
Technique:  in situ hybridisation.
References:  41
CNS: cortex, hippocampus, amygdala, thalamus, hypothalamus, mesencephalon, pons.
Species:  Rat
Technique:  in situ hybridisation.
References:  26
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of Ca2+ levels in human neuroblastoma CHP-234 cells endogenously expressing the Y2 receptor.
Species:  Human
Tissue:  CHP-234 cells.
Response measured:  Stimulation of Ca2+ accumulation.
References:  36
Measurement of cAMP levels in human neuroblastoma SMS-KAN cells endogenously expressing the Y2 receptor.
Species:  Human
Tissue:  SMS-KAN cells.
Response measured:  Inhibition of forskolin-stimulated cAMP accumulation.
References:  50
Measurement of Ca2+ levels in human neuroblastoma SMS-KAN cells endogenously expressing the Y2 receptor.
Species:  Human
Tissue:  SMS-KAN cells.
Response measured:  Stimulation of Ca2+ release from intracellular stores and K+-induced Ca2+ influx.
References:  50
Physiological Functions
Contraction.
Species:  Rat
Tissue:  Colon.
References:  20,42
Modulation of anxiety-related behaviour.
Species:  Mouse
Tissue:  In vivo.
References:  38
Modulation of anxiety-related behaviour.
Species:  Rat
Tissue:  In vivo.
References:  30,48
Stimulation of ethanol consumption.
Species:  Rat
Tissue:  In vivo.
References:  54
Inhibition of food intake.
Species:  Rat
Tissue:  In vivo.
References:  7,49
Inhibition of food intake.
Species:  Human
Tissue:  In vivo.
References:  6-7
Modulation of duodenal motility.
Species:  Rat
Tissue:  In vivo.
References:  19
Stimulation of non-rapid eye movement sleep.
Species:  Rat
Tissue:  In vivo (eye).
References:  1
Angiogenesis.
Species:  Rat
Tissue:  In vivo.
References:  57
Inhibition of electrogenic ion transport.
Species:  Human
Tissue:  Isolated descending colon.
References:  14
Inhibition of electrogenic ion transport.
Species:  Mouse
Tissue:  Colonic mucosal preparaions.
References:  13
Presynaptic inhibition.
Species:  Rat
Tissue:  Hippocampal slices.
References:  12
Physiological Consequences of Altering Gene Expression
Y2 receptor knockout mice exhibit potentiation of pentobarbital-induced sedation.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  40
Y2 receptor knockout mice exhibit alterations in bone homeostasis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  2,4
Hypothalamus-specific Y2 receptor knockout mice exhibit a decrease in body weight, increase in food intake and an increase in plasma concentrations of pancreatic polypeptide and corticosterone.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  47
Y2 receptor knockout mice do not exhibit inhibition of food intake, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  6-7
Y2 receptor knockout mice do not exhibit agonist-induced angiogenesis, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  16,32-33
Y2 receptor knockout mice exhibit delayed wound healing.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  16
Y2 receptor knockout mice exhibit reduced levels of anxiety-related behaviour compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  11,25,43,55
Y2 receptor knockout mice exhibit impaired learning and memory.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  44
Y2 receptor knockout mice exhibit a decrease in ethanol consumption and an increase in water consumption.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  53
Y2 receptor knockout mice do not exhibit resetting of the circadian clock, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  51
Y2 receptor knockout mice exhibit an increase in water consumption during the dark phase.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  56
Y2 receptor knockout mice do not exhibit the antagonist-induced increase in mucosal ion transport as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  27
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0005452 abnormal adipose tissue amount PMID: 12453895 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0002896 abnormal bone mineralization PMID: 11927618 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0002896 abnormal bone mineralization PMID: 12861009 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0008271 abnormal bone ossification PMID: 11927618 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0003795 abnormal bone structure PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0000130 abnormal cancellous bone morphology PMID: 11927618 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0000130 abnormal cancellous bone morphology PMID: 11927618 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0000130 abnormal cancellous bone morphology PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:108418  MP:0000130 abnormal cancellous bone morphology PMID: 12861009 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0000188 abnormal circulating glucose level PMID: 12453895 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0005418 abnormal circulating hormone level PMID: 12072562 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0001560 abnormal circulating insulin level PMID: 12453895 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0001560 abnormal circulating insulin level PMID: 12072562 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0008459 abnormal circulating pancreatic peptide level PMID: 12072562 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0008459 abnormal circulating pancreatic peptide level PMID: 12072562 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0008459 abnormal circulating pancreatic peptide level PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:108418  MP:0008459 abnormal circulating pancreatic peptide level PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0001422 abnormal drinking behavior PMID: 16364461 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c
MGI:108418  MP:0005449 abnormal food intake PMID: 10502824 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0005449 abnormal food intake PMID: 12072562 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ
MGI:108418  MP:0005449 abnormal food intake PMID: 16950139 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0003953 abnormal hormone level PMID: 17272395 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:105374  MGI:108418  MP:0003953 abnormal hormone level PMID: 17272395 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0000477 abnormal intestine morphology PMID: 12453895 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0002801 abnormal long term object recognition memory PMID: 14997009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0006092 abnormal olfactory neuron morphology PMID: 18305161 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0005006 abnormal osteoblast physiology PMID: 12861009 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0000057 abnormal osteogenesis PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0004275 abnormal postnatal subventricular zone morphology PMID: 18305161 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0004279 abnormal rostral migratory stream morphology PMID: 18305161 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv
MGI:108418  MP:0001501 abnormal sleep pattern PMID: 11579129 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0001463 abnormal spatial learning PMID: 14997009 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/cJ
MGI:108418  MP:0002570 alcohol aversion PMID: 15203244 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv
MGI:108418  MP:0002862 altered righting response PMID: 11579129 
Npy1rtm1Pern|Npy2rtm1Pern Npy1rtm1Pern/Npy1rtm1Pern,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv
MGI:104963  MGI:108418  MP:0002862 altered righting response PMID: 11579129 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0001364 decreased anxiety-related response PMID: 12742262 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0001262 decreased body weight PMID: 12072562 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0001262 decreased body weight PMID: 12072562 
Lepob|Npy2rtm1Pern Lepob/Lepob,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:108418  MP:0001262 decreased body weight PMID: 12126735 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0001262 decreased body weight PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:108418  MP:0001262 decreased body weight PMID: 12861009 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0001780 decreased brown adipose tissue amount PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0002665 decreased circulating corticosterone level PMID: 12453895 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0002665 decreased circulating corticosterone level PMID: 12453895 
Lepob|Npy2rtm1Pern Lepob/Lepob,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:108418  MP:0002702 decreased circulating free fatty acid level PMID: 12126735 
Lepob|Npy2rtm1Pern Lepob/Lepob,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:108418  MP:0005560 decreased circulating glucose level PMID: 12126735 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0002727 decreased circulating insulin level PMID: 12072562 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0002727 decreased circulating insulin level PMID: 12861009 
Lepob|Npy2rtm1Pern Lepob/Lepob,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:108418  MP:0000183 decreased circulating LDL cholesterol level PMID: 12126735 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0005668 decreased circulating leptin level PMID: 12861009 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0002780 decreased circulating testosterone level PMID: 12453895 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0000135 decreased cortical bone thickness PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0003910 decreased eating behavior PMID: 12072562 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:108418  MP:0003910 decreased eating behavior PMID: 12861009 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c
MGI:108418  MP:0004890 decreased energy expenditure PMID: 10502824 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0009289 decreased epididymal fat pad weight PMID: 12453895 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0003961 decreased lean body mass PMID: 12453895 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0009299 decreased mesenteric fat pad weight PMID: 12453895 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0004981 decreased neuronal precursor cell number PMID: 18305161 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0004985 decreased osteoclast cell number PMID: 11927618 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:108418  MP:0004985 decreased osteoclast cell number PMID: 12861009 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0004852 decreased testis weight PMID: 12453895 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0001783 decreased white adipose tissue amount PMID: 12072562 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0001783 decreased white adipose tissue amount PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:108418  MP:0001783 decreased white adipose tissue amount PMID: 12861009 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0001926 female infertility PMID: 12000791 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c
MGI:108418  MP:0001402 hypoactivity PMID: 10502824 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c
MGI:108418  MP:0001260 increased body weight PMID: 10502824 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0001260 increased body weight PMID: 12453895 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0009347 increased cancellous bone thickness PMID: 11927618 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0009347 increased cancellous bone thickness PMID: 11927618 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0009347 increased cancellous bone thickness PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:108418  MP:0009347 increased cancellous bone thickness PMID: 12861009 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0005178 increased circulating cholesterol level PMID: 12453895 
Lepob|Npy2rtm1Pern Lepob/Lepob,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:108418  MP:0005178 increased circulating cholesterol level PMID: 12126735 
Npy2rtm1Hhz Npy2rtm1Hhz/Npy2rtm1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0001745 increased circulating corticosterone level PMID: 11927618  12072562 
Lepob|Npy2rtm1Pern Lepob/Lepob,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:108418  MP:0001556 increased circulating HDL cholesterol level PMID: 12126735 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0004702 increased circulating insulin-like growth factor I level PMID: 17272395 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:105374  MGI:108418  MP:0004702 increased circulating insulin-like growth factor I level PMID: 17272395 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0001552 increased circulating triglyceride level PMID: 12453895 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0003911 increased drinking behavior PMID: 16364461 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/cJ
MGI:108418  MP:0003911 increased drinking behavior PMID: 15203244 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * BALB/cJ * C57BL/6
MGI:105374  MGI:108418  MP:0003909 increased eating behavior PMID: 12861009 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0005137 increased growth hormone level PMID: 17272395 
Npy2rtm1.1Hhz|Ppyr1tm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz,Ppyr1tm1.1Hhz/Ppyr1tm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:105374  MGI:108418  MP:0005137 increased growth hormone level PMID: 17272395 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c
MGI:108418  MP:0002626 increased heart rate PMID: 10502824 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0003917 increased kidney weight PMID: 12453895 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0002981 increased liver weight PMID: 12453895 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0009108 increased pancreas weight PMID: 12453895 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0009766 increased sensitivity to xenobiotic induced morbidity/mortality PMID: 16650144 
Npy2rtm1.1Hhz Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:108418  MP:0002906 increased susceptibility to pharmacologically induced seizures PMID: 16650144 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c
MGI:108418  MP:0008908 increased total fat pad weight PMID: 10502824 
Lepob|Npy2rtm1Pern Lepob/Lepob,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:108418  MP:0005317 increased triglyceride level PMID: 12126735 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0001925 male infertility PMID: 12000791  12453895 
Npy2rtm1Pern Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv * BALB/c
MGI:108418  MP:0001433 polyphagia PMID: 10502824 
Lepob|Npy2rtm1.1Hhz Lepob/Lepob,Npy2rtm1.1Hhz/Npy2rtm1.1Hhz
involves: 129X1/SvJ * C57BL/6
MGI:104663  MGI:108418  MP:0001433 polyphagia PMID: 12453895 
Biologically Significant Variants
Type:  Single nucleotide polymorphism
Species:  Human
Description:  A Thr585 -> Cys polymorphism has been linked to obesity in Swedish Caucasian men.
Amino acid change:  T585C
References:  31
General Comments
For a review on NPY receptor knockout mice see [34].
For a review on the functions of the Y2 receptor see [29].

References

Show »

1. Akanmu MA, Ukponmwan OE, Katayama Y, Honda K. (2006) Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat. Neurosci Res, 54: 165-170. [PMID:16378653]

2. Allison SJ, Baldock P, Sainsbury A, Enriquez R, Lee NJ, Lin EJ, Klugman M, During M, Eisman JA, Li M, Pan LC, Herzog H, Gardiner EM. (2006) Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J Biol Chem, 281: 23436-23444. [PMID:16785231]

3. Ammar DA, Eadie DM, Wong DJ, Ma YY, Kolakowski LF, Yang-Feng TL, Thompson DA. (1996) Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. Genomics, 38: 392-398. [PMID:8975716]

4. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H. (2002) Hypothalamic Y2 receptors regulate bone formation. J Clin Invest, 109: 915-921. [PMID:11927618]

5. Barrios VE, Sun J, Douglass J, Toombs CF. (1999) Evidence of a specific pancreatic polypeptide receptor in rat arterial smooth muscle. Peptides, 20: 1107-1113. [PMID:10499429]

6. Batterham RL, Bloom SR. (2003) The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci, 994: 162-168. [PMID:12851312]

7. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature, 418: 650-654. [PMID:12167864]

8. Bonaventure P, Nepomuceno D, Mazur C, Lord B, Rudolph DA, Jablonowski JA, Carruthers NI, Lovenberg TW. (2004) Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor. J. Pharmacol. Exp. Ther., 308 (3): 1130-7. [PMID:14617685]

9. Caberlotto L, Fuxe K, Rimland JM, Sedvall G, Hurd YL. (1998) Regional distribution of neuropeptide Y Y2 receptor messenger RNA in the human post mortem brain. Neuroscience, 86: 167-178. [PMID:9692752]

10. Cabrele C, Wieland HA, Koglin N, Stidsen C, Beck-Sickinger AG. (2002) Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry, 41: 8043-8049. [PMID:12069595]

11. Carvajal C, Dumont Y, Herzog H, Quirion R. (2006) Emotional behavior in aged neuropeptide Y (NPY) Y2 knockout mice. J Mol Neurosci, 28: 239-245. [PMID:16691011]

12. Colmers WF, Klapstein GJ, Fournier A, St-Pierre S, Treherne KA. (1991) Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor. Br J Pharmacol, 102: 41-44. [PMID:1646061]

13. Cox HM, Pollock EL, Tough IR, Herzog H. (2001) Multiple Y receptors mediate pancreatic polypeptide responses in mouse colon mucosa. Peptides, 22: 445-452. [PMID:11287100]

14. Cox HM, Tough IR. (2002) Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol, 135: 1505-1512. [PMID:11906964]

15. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K. (1999) BIIE0246: A selective and high affinity neuropeptide Y Y2 receptor antagonist. Eur. J. Pharmacol., 384: R3-R5. [PMID:10611450]

16. Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander AC, Hassani H, Hallberg B, Nordlander M, Cao Y. (2003) Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A, 100: 6033-6038. [PMID:12730369]

17. Ferrier L, Segain JP, Bonnet C, Cherbut C, Lehur PA, Jarry A, Galmiche JP, Blottiere HM. (2002) Functional mapping of NPY/PYY receptors in rat and human gastro-intestinal tract. Peptides, 23: 1765-1771. [PMID:12383864]

18. Fetissov SO, Byrne LC, Hassani H, Ernfors P, Hökfelt T. (2004) Characterization of neuropeptide Y Y2 and Y5 receptor expression in the mouse hypothalamus. J Comp Neurol, 470: 256-265. [PMID:14755515]

19. Fujimiya M, Itoh E, Kihara N, Yamamoto I, Fujimura M, Inui A. (2000) Neuropeptide Y induces fasted pattern of duodenal motility via Y(2) receptors in conscious fed rats. Am J Physiol Gastrointest Liver Physiol, 278: G32-G38. [PMID:10644559]

20. Félétou M, Rodriguez M, Beauverger P, Germain M, Imbert J, Dromaint S, Macia C, Bourrienne A, Henlin JM, Nicolas JP, Boutin JA, Galizzi JP, Fauchere JL, Canet E, Duhault J. (1998) NPY receptor subtypes involved in the contraction of the proximal colon of the rat. Regul Pept, 75-76: 221-229. [PMID:9802413]

21. Gehlert DR, Beavers LS, Johnson D, Gackenheimer SL, Schober DA, Gadski RA. (1996) Expression cloning of a human brain neuropeptide Y Y2 receptor. Mol Pharmacol, 49: 224-228. [PMID:8632753]

22. Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL. (1995) Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem, 270: 26758-26761. [PMID:7592910]

23. Goumain M, Voisin T, Lorinet AM, Ducroc R, Tsocas A, Rozé C, Rouet-Benzineb P, Herzog H, Balasubramaniam A, Laburthe M. (2001) The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning. Mol Pharmacol, 60: 124-134. [PMID:11408607]

24. Goumain M, Voisin T, Lorinet AM, Laburthe M. (1998) Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon. Biochem Biophys Res Commun, 247: 52-56. [PMID:9636652]

25. Greco B, Carli M. (2006) Reduced attention and increased impulsivity in mice lacking NPY Y2 receptors: relation to anxiolytic-like phenotype. Behav Brain Res, 169: 325-334. [PMID:16529827]

26. Gustafson EL, Smith KE, Durkin MM, Walker MW, Gerald C, Weinshank R, Branchek TA. (1997) Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system. Brain Res Mol Brain Res, 46: 223-235. [PMID:9191097]

27. Hyland NP, Sjöberg F, Tough IR, Herzog H, Cox HM. (2003) Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues. Br J Pharmacol, 139: 863-871. [PMID:12813010]

28. Jönsson-Rylander AC, Nordlander M, Svindland A, Ilebekk A. (2003) Distribution of neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. Peptides, 24: 255-262. [PMID:12668210]

29. Kaga T, Fujimiya M, Inui A. (2001) Emerging functions of neuropeptide Y Y(2) receptors in the brain. Peptides, 22: 501-506. [PMID:11287107]

30. Kask A, Rägo L, Harro J. (1998) Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13-36 microinjected into vicinity of locus coeruleus in rats. Brain Res, 788: 345-348. [PMID:9555090]

31. Lavebratt C, Alpman A, Persson B, Arner P, Hoffstedt J. (2006) Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Int J Obes (Lond), 30: 453-459. [PMID:16331299]

32. Lee EW, Grant DS, Movafagh S, Zukowska Z. (2003) Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides, 24: 99-106. [PMID:12576090]

33. Lee EW, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P, Sangkharat A, Ji H, Li L, Michalkiewicz T, Ljubisavljevic M, Johansson H, Grant DS, Zukowska Z. (2003) Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest, 111: 1853-1862. [PMID:12813021]

34. Lin S, Boey D, Herzog H. (2004) NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides, 38: 189-200. [PMID:15337371]

35. Lutz CM, Frankel WN, Richards JE, Thompson DA. (1997) Neuropeptide Y receptor genes on human chromosome 4q31-q32 map to conserved linkage groups on mouse chromosomes 3 and 8. Genomics, 41: 498-500. [PMID:9169155]

36. Lynch JW, Lemos VS, Bucher B, Stoclet JC, Takeda K. (1994) A pertussis toxin-insensitive calcium influx mediated by neuropeptide Y2 receptors in a human neuroblastoma cell line. J Biol Chem, 269: 8226-8233. [PMID:8132547]

37. Misra S, Murthy KS, Zhou H, Grider JR. (2004) Coexpression of Y1, Y2, and Y4 receptors in smooth muscle coupled to distinct signaling pathways. J Pharmacol Exp Ther, 311: 1154-1162. [PMID:15308651]

38. Nakajima M, Inui A, Asakawa A, Momose K, Ueno N, Teranishi A, Baba S, Kasuga M. (1998) Neuropeptide Y produces anxiety via Y2-type receptors. Peptides, 19: 359-363. [PMID:9493869]

39. Nakamura M, Aoki Y, Hirano D. (1996) Cloning and functional expression of a cDNA encoding a mouse type 2 neuropeptide Y receptor. Biochim Biophys Acta, 1284: 134-137. [PMID:8914576]

40. Naveilhan P, Canals JM, Arenas E, Ernfors P. (2001) Distinct roles of the Y1 and Y2 receptors on neuropeptide Y-induced sensitization to sedation. J Neurochem, 78: 1201-1207. [PMID:11579129]

41. Parker RM, Herzog H. (1999) Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci, 11: 1431-1448. [PMID:10103138]

42. Pheng LH, Perron A, Quirion R, Cadieux A, Fauchere JL, Dumont Y, Regoli D. (1999) Neuropeptide Y-induced contraction is mediated by neuropeptide Y Y2 and Y4 receptors in the rat colon. Eur J Pharmacol, 374: 85-91. [PMID:10422644]

43. Redrobe JP, Dumont Y, Herzog H, Quirion R. (2003) Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav Brain Res, 141: 251-255. [PMID:12742262]

44. Redrobe JP, Dumont Y, Herzog H, Quirion R. (2004) Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci, 22: 159-166. [PMID:14997009]

45. Rimland JM, Seward EP, Humbert Y, Ratti E, Trist DG, North RA. (1996) Coexpression with potassium channel subunits used to clone the Y2 receptor for neuropeptide Y. Mol Pharmacol, 49: 387-390. [PMID:8643076]

46. Rose PM, Fernandes P, Lynch JS, Frazier ST, Fisher SM, Kodukula K, Kienzle B, Seethala R. (1995) Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem, 270: 22661-22664. [PMID:7559383]

47. Sainsbury A, Schwarzer C, Couzens M, Fetissov S, Furtinger S, Jenkins A, Cox HM, Sperk G, Hökfelt T, Herzog H. (2002) Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci U S A, 99: 8938-8943. [PMID:12072562]

48. Sajdyk TJ, Schober DA, Smiley DL, Gehlert DR. (2002) Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav, 71: 419-423. [PMID:11830176]

49. Scott V, Kimura N, Stark JA, Luckman SM. (2005) Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J Neuroendocrinol, 17: 452-457. [PMID:15946163]

50. Shigeri Y, Fujimoto M. (1994) Y2 receptors for neuropeptide Y are coupled to three intracellular signal transduction pathways in a human neuroblastoma cell line. J Biol Chem, 269: 8842-8848. [PMID:8132619]

51. Soscia SJ, Harrington ME. (2005) Neuropeptide Y does not reset the circadian clock in NPY Y2-/- mice. Neurosci Lett, 373: 175-178. [PMID:15619538]

52. Stanic D, Brumovsky P, Fetissov S, Shuster S, Herzog H, Hökfelt T. (2006) Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals. J Comp Neurol, 499: 357-390. [PMID:16998904]

53. Thiele TE, Naveilhan P, Ernfors P. (2004) Assessment of ethanol consumption and water drinking by NPY Y(2) receptor knockout mice. Peptides, 25: 975-983. [PMID:15203244]

54. Thorsell A, Rimondini R, Heilig M. (2002) Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats. Neurosci Lett, 332: 1-4. [PMID:12377370]

55. Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, Herzog H, Sperk G. (2003) Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci, 18: 143-148. [PMID:12859347]

56. Wultsch T, Painsipp E, Donner S, Sperk G, Herzog H, Peskar BA, Holzer P. (2006) Selective increase of dark phase water intake in neuropeptide-Y Y2 and Y4 receptor knockout mice. Behav Brain Res, 168: 255-260. [PMID:16364461]

57. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS. (1998) Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res, 83: 187-195. [PMID:9686758]

Contributors

Show »

How to cite this page

Annette Beck-Sickinger, William F. Colmers, Helen M. Cox, Henri N. Doods, Herbert Herzog, Dan Larhammar, Martin C. Michel, Remi Quirion, Thue Schwartz, Thomas Westfall.
Neuropeptide Y receptors: Y2 receptor. Last modified on 20/02/2018. Accessed on 13/11/2018. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=306.